CoChat

Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To compare the efficacy and safety of adding mealtime pramlintide or rapid-acting insulin analogs (RAIAs) to basal insulin for patients with inadequately controlled type 2 diabetes. RESEARCH DESIGN AND METHODS: In a 24-week open-label, multicenter study, 113 patients were randomly assigned 1:1 to addition of mealtime pramlintide (120 μg) or a titrated RAIA to basal insulin and prior oral antihyperglycemic drugs (OADs). At screening, patients were insulin naive or had been receiving <50 units/day basal insulin for <6 months. The basal insulin dosage was titrated from day 1, seeking fasting plasma glucose (FPG) ≥70–<100 mg/dl. Pramlintide and an RAIA were initiated on day 1 and week 4, respectively. The proportion of patients achieving A1C ≤7.0% without weight gain or severe hypoglycemia at week 24 was the primary end point. RESULTS: More pramlintide- than RAIA-treated patients achieved the primary end point (30 vs. 11%, P = 0.018) with a similar dose of basal insulin. Pramlintide and an RAIA yielded similar mean ± SEM values for FPG and A1C at 24 weeks (122 ± 7 vs. 123 ± 5 mg/dl and 7.2 ± 0.2 vs. 7.0 ± 0.1%, respectively) and similar least squares mean reductions from baseline to end point (−31 ± 6 vs. −34 ± 6 mg/dl and −1.1 ± 0.2 vs. −1.3 ± 0.2%, respectively). RAIAs but not pramlintide caused weight gain (+4.7 ± 0.7 vs. +0.0 ± 0.7 kg, P < 0.0001). Fewer patients reported mild to moderate hypoglycemia with pramlintide than with the RAIA (55 vs. 82%), but more patients reported nausea (21 vs. 0%). No severe hypoglycemia occurred in either group. CONCLUSIONS: In patients taking basal insulin and OADs, premeal fixed-dose pramlintide improved glycemic control as effectively as titrated RAIAs. The pramlintide regimen sometimes caused nausea but no weight gain and less hypoglycemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-0395

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 A: Mean changes in insulin dosage over the course of the trial. Solid squares, unbroken line = basal insulin in the pramlintide group. Open triangles, unbroken line = basal insulin in the RAIA group. Open circles, broken line = total insulin (basal plus mealtime) in the RAIA group. B: Mean A1C at each visit. Solid squares = pramlintide; open circles = RAIA. C: Least squares mean weight changes over time with the last observation carried forward. Solid squares = pramlintide; open circles = RAIA. ***P < 0.001; **P < 0.01. D: Mean fasting plasma glucose over time. Solid squares = pramlintide; open circles = RAIA. LOCF, last observation carried forward; LS, least squares.
Figure 1 A: Mean changes in insulin dosage over the course of the trial. Solid squares, unbroken line = basal insulin in the pramlintide group. Open triangles, unbroken line = basal insulin in the RAIA group. Open circles, broken line = total insulin (basal plus mealtime) in the RAIA group. B: Mean A1C at each visit. Solid squares = pramlintide; open circles = RAIA. C: Least squares mean weight changes over time with the last observation carried forward. Solid squares = pramlintide; open circles = RAIA. ***P < 0.001; **P < 0.01. D: Mean fasting plasma glucose over time. Solid squares = pramlintide; open circles = RAIA. LOCF, last observation carried forward; LS, least squares.CC BY-NC-ND · PubMed Central
Figure 2 A: Postprandial glucose increments from before to after meals at 24 weeks. Black bars = pramlintide; white bars = RAIA. B: Incidence and severity of hypoglycemia and nausea in patients treated with pramlintide or RAIA in addition to basal insulin. White bar = mild; striped bar = mild or moderate; cross-hatched bar = moderate; black bar = severe. C: The rate of hypoglycemia (events/week) over the course of the study with RAIA and pramlintide treatment. Black bars = pramlintide; white bars = RAIA. D: Number of patients reporting nausea over time during treatment with pramlintide.
Figure 2 A: Postprandial glucose increments from before to after meals at 24 weeks. Black bars = pramlintide; white bars = RAIA. B: Incidence and severity of hypoglycemia and nausea in patients treated with pramlintide or RAIA in addition to basal insulin. White bar = mild; striped bar = mild or moderate; cross-hatched bar = moderate; black bar = severe. C: The rate of hypoglycemia (events/week) over the course of the study with RAIA and pramlintide treatment. Black bars = pramlintide; white bars = RAIA. D: Number of patients reporting nausea over time during treatment with pramlintide.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

Metadata

Authors
Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L.
Affiliations
  • Oregon Health & Science University (US)
  • Amylin Pharmaceuticals, San Diego, California.
Corresponding author
Wilhelm, Ken
Venue
Diabetes Care
Published
2009-06-05
Volume
32
Issue
9
Pages
1577-1582
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2143946880
Cited by
66
References
27
Citations by year
2025: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2019: 1 · 2018: 1 · 2017: 7 · 2016: 4 · 2015: 5 · 2014: 2 · 2013: 10 · 2012: 5
FWCI
7.02
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
pramlintide, rapid-acting insulin analogs, basal insulin, type 2 diabetes, glycemic control, HbA1c, weight gain, hypoglycemia, nausea, insulin-naive patients, oral antidiabetic drugs, insulin therapy intensification, insulin sensitivity
MeSH terms
Adolescent, Adult, Aged, Amyloid, Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Treatment Outcome, Postprandial Period, Insulin, Long-Acting, Young Adult, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.